<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Ornithine Carbamoyltransferase Deficiency - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-name-link {
            color: inherit;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
        }

        .item-name-link:hover {
            text-decoration-thickness: 2px;
        }

        .missing-disease-name {
            color: #991b1b;
            border-bottom: 1px dotted #dc2626;
        }

        .curation-gap-badge {
            display: inline-flex;
            align-items: center;
            margin-left: 8px;
            padding: 2px 8px;
            border-radius: 999px;
            font-size: 0.72rem;
            font-weight: 700;
            letter-spacing: 0.01em;
            text-transform: uppercase;
            background: #fef2f2;
            border: 1px solid #fecaca;
            color: #b91c1c;
            vertical-align: middle;
        }

        .missing-ontology-link {
            color: #b91c1c !important;
            text-decoration: underline dotted;
            text-underline-offset: 2px;
        }

        .dismech-inline-link {
            margin-left: 6px;
            font-size: 0.78rem;
            font-weight: 600;
            color: #0369a1;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
            white-space: nowrap;
        }

        .dismech-inline-link:hover {
            text-decoration-thickness: 2px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "↳ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Ornithine Carbamoyltransferase Deficiency</span>
        </nav>

        <header class="page-header">
            <h1>Ornithine Carbamoyltransferase Deficiency</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Mendelian</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0010703" target="_blank">
                        MONDO:0010703
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Urea Cycle Disorder</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Inborn Error of Metabolism</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Ornithine carbamoyltransferase deficiency (OTCD) is the most common urea cycle disorder, caused by pathogenic variants in the X-linked OTC gene. The encoded mitochondrial enzyme catalyzes the conversion of carbamoyl phosphate and ornithine to citrulline. Deficiency impairs ureagenesis, producing episodic or persistent hyperammonemia with risk of severe neurologic injury. Hemizygous males typically present with neonatal-onset disease, whereas heterozygous females and males with partial enzyme deficiency may present with later-onset intermittent hyperammonemia triggered by catabolic stress.

            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">13</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Ornithine carbamoyltransferase molecular function deficiency</div>
                
                <div class="item-desc">Pathogenic OTC variants reduce ornithine carbamoyltransferase enzymatic activity in hepatic mitochondria.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        hepatocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000182" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-gene">
                        OTC
                        
                        <a href="https://bioregistry.io/hgnc:8512" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        liver
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002107" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31441224" target="_blank">PMID:31441224</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Ornithine transcarbamylase deficiency (OTCD) is a rare X-linked urea cycle disorder."</div>
                
                
                <div class="evidence-explanation">Supports OTCD as a urea-cycle enzyme deficiency disorder.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31110235" target="_blank">PMID:31110235</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"carbamoylphosphate synthetase 1 and ornithine transcarbamylase are present in the mitochondrial matrix"</div>
                
                
                <div class="evidence-explanation">Confirms mitochondrial matrix localization of OTC enzyme.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Impaired citrulline synthesis and reduced urea cycle flux</div>
                
                <div class="item-desc">Reduced OTC activity lowers conversion of ornithine and carbamoyl phosphate to citrulline, decreasing urea cycle throughput and predisposing to hyperammonemia.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        urea cycle
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0000050" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39328593" target="_blank">PMID:39328593</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"OTCD typically leads to mitochondrial enzyme dysfunction, preventing the synthesis of citrulline from carbamoyl phosphate and ornithine"</div>
                
                
                <div class="evidence-explanation">Directly supports the enzymatic defect blocking citrulline synthesis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Hyperammonemic cerebral injury via astrocyte swelling</div>
                
                <div class="item-desc">Recurrent hyperammonemia causes astrocyte swelling and cerebral edema through glutamine accumulation. In brain, glutamine synthesis is the only route of ammonia detoxification, and excess glutamine acts as an osmolyte causing astrocyte swelling and cerebral edema.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        astrocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000127" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        glutamine biosynthetic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006541" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        brain
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000955" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36128655" target="_blank">PMID:36128655</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Its clinical manifestations are mainly central nervous system dysfunction caused by high blood ammonia."</div>
                
                
                <div class="evidence-explanation">Supports ammonia-driven CNS injury as a core downstream mechanism.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34665389" target="_blank">PMID:34665389</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"severe damage to the central nervous system due to the toxic effects exerted by ammonia on the astrocytes"</div>
                
                
                <div class="evidence-explanation">Directly supports astrocyte-mediated ammonia neurotoxicity.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35733937" target="_blank">PMID:35733937</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"in brain glutamine synthesis is the only route of ammonia detoxification, hyperammonemia is as a rule associated with increased brain glutamine content (glutaminosis)"</div>
                
                
                <div class="evidence-explanation">Supports the glutamine trapping hypothesis and osmotic astrocyte swelling mechanism.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Ammonia-induced oxidative stress and mitochondrial dysfunction</div>
                
                <div class="item-desc">Hyperammonemia induces oxidative stress and mitochondrial dysfunction in the CNS, contributing to neuronal energy failure and cumulative neurodevelopmental impairment.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        response to oxidative stress
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006979" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34665389" target="_blank">PMID:34665389</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Ammonia is a neurotoxic compound which is detoxified through liver enzymes from urea cycle."</div>
                
                
                <div class="evidence-explanation">Supports the neurotoxic role of ammonia when hepatic detoxification is impaired.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Carbamoyl phosphate diversion to pyrimidine pathway</div>
                
                <div class="item-desc">When OTC cannot utilize carbamoyl phosphate, excess substrate enters the cytosolic pyrimidine biosynthesis pathway, resulting in increased urinary orotic acid excretion, a hallmark diagnostic finding in OTCD.
</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39220945" target="_blank">PMID:39220945</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"all ten early-onset cases had glutamine concentrations above the upper limit, only five of them had citrulline concentrations below the lower limit"</div>
                
                
                <div class="evidence-explanation">Supports the biochemical pattern of impaired citrulline synthesis with substrate diversion.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">⬡</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    Impaired_citrulline_synthesis_and_reduced_urea_cycle_flux[&#34;Impaired citrulline synthesis and reduced urea cycle flux&#34;]
    Hyperammonemic_cerebral_injury_via_astrocyte_swelling[&#34;Hyperammonemic cerebral injury via astrocyte swelling&#34;]
    Ammonia_induced_oxidative_stress_and_mitochondrial_dysfunction[&#34;Ammonia-induced oxidative stress and mitochondrial dysfunction&#34;]
    Ornithine_carbamoyltransferase_molecular_function_deficiency[&#34;Ornithine carbamoyltransferase molecular function deficiency&#34;]
    Carbamoyl_phosphate_diversion_to_pyrimidine_pathway[&#34;Carbamoyl phosphate diversion to pyrimidine pathway&#34;]

    Ornithine_carbamoyltransferase_molecular_function_deficiency --&gt; Impaired_citrulline_synthesis_and_reduced_urea_cycle_flux
    Impaired_citrulline_synthesis_and_reduced_urea_cycle_flux --&gt; Hyperammonemic_cerebral_injury_via_astrocyte_swelling
    Impaired_citrulline_synthesis_and_reduced_urea_cycle_flux --&gt; Carbamoyl_phosphate_diversion_to_pyrimidine_pathway
    Hyperammonemic_cerebral_injury_via_astrocyte_swelling --&gt; Ammonia_induced_oxidative_stress_and_mitochondrial_dysfunction

    style Impaired_citrulline_synthesis_and_reduced_urea_cycle_flux fill:#dbeafe
    style Hyperammonemic_cerebral_injury_via_astrocyte_swelling fill:#dbeafe
    style Ammonia_induced_oxidative_stress_and_mitochondrial_dysfunction fill:#dbeafe
    style Ornithine_carbamoyltransferase_molecular_function_deficiency fill:#dbeafe
    style Carbamoyl_phosphate_diversion_to_pyrimidine_pathway fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">13</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Digestive<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Nervous System<span class="pill-count">(6)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Other<span class="pill-count">(6)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Digestive
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Vomiting
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002013" target="_blank">
                                Vomiting
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002013)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36128655" target="_blank">PMID:36128655</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"His first symptoms were nonprojectile vomiting, followed by irritability and disturbance of consciousness, after which the disease progressed rapidly and finally resulted in a coma."</div>
                
                
                <div class="evidence-explanation">Directly supports vomiting as an early symptom in hyperammonemic decompensation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Nervous System
                    <span class="cat-count">6</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Encephalopathy
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001298" target="_blank">
                                Encephalopathy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001298)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36128655" target="_blank">PMID:36128655</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Its clinical manifestations are mainly central nervous system dysfunction caused by high blood ammonia."</div>
                
                
                <div class="evidence-explanation">Supports encephalopathic CNS dysfunction in OTCD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33409766" target="_blank">PMID:33409766</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Hyperammonemia caused by a disorder of the urea cycle is a rare cause of metabolic encephalopathy that may be underdiagnosed by the adult intensivists because of its rarity."</div>
                
                
                <div class="evidence-explanation">Directly identifies UCD-related hyperammonemia as a cause of metabolic encephalopathy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Lethargy
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001254" target="_blank">
                                Lethargy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001254)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36128655" target="_blank">PMID:36128655</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"His first symptoms were nonprojectile vomiting, followed by irritability and disturbance of consciousness, after which the disease progressed rapidly and finally resulted in a coma."</div>
                
                
                <div class="evidence-explanation">Supports severe neurologic decline during OTCD decompensation episodes.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Seizures
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001250" target="_blank">
                                Seizure
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001250)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39256843" target="_blank">PMID:39256843</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Five boys presented with early-onset symptoms, including poor appetite, drowsiness, groaning, seizures, and liver failure."</div>
                
                
                <div class="evidence-explanation">Directly reports seizures as a clinical manifestation in early-onset OTCD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Coma
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001259" target="_blank">
                                Coma
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001259)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37146589" target="_blank">PMID:37146589</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"rapidly develop hyperammonemia, which can progress to cerebral edema, coma, and death"</div>
                
                
                <div class="evidence-explanation">Directly supports coma as a progression of hyperammonemia in OTCD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36128655" target="_blank">PMID:36128655</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"the disease progressed rapidly and finally resulted in a coma"</div>
                
                
                <div class="evidence-explanation">Case report documenting progression to coma in late-onset OTCD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Global developmental delay
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001263" target="_blank">
                                Global developmental delay
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001263)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36128655" target="_blank">PMID:36128655</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"However, the child is currently mentally retarded, and the language center has not yet fully recovered."</div>
                
                
                <div class="evidence-explanation">Supports persistent neurodevelopmental impairment after severe OTCD CNS injury.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Behavioral abnormalities
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000708" target="_blank">
                                Atypical behavior
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000708)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Behavioral disorders reported in 35% of adult-onset UCD presentations in systematic reviews.</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">6</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hyperammonemia
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001987" target="_blank">
                                Hyperammonemia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001987)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31441224" target="_blank">PMID:31441224</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Maternal OTCD can lead to life-threatening hyperammonemia if untreated."</div>
                
                
                <div class="evidence-explanation">Confirms hyperammonemia as a major clinical risk in OTCD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37146589" target="_blank">PMID:37146589</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Individuals with neonatal onset appear normal at birth but rapidly develop hyperammonemia, which can progress to cerebral edema, coma, and death"</div>
                
                
                <div class="evidence-explanation">Confirms hyperammonemia as the pivotal early clinical event in neonatal OTCD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Cerebral edema
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002181" target="_blank">
                                Cerebral edema
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002181)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37146589" target="_blank">PMID:37146589</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"rapidly develop hyperammonemia, which can progress to cerebral edema, coma, and death"</div>
                
                
                <div class="evidence-explanation">Directly names cerebral edema as a complication of hyperammonemia in OTCD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33409766" target="_blank">PMID:33409766</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"emergent hemodialysis is mandatory before referral to a reference center if ammonia levels are above 200 µmol/l as the risk of cerebral edema is then above 55%"</div>
                
                
                <div class="evidence-explanation">Quantifies the high risk of cerebral edema at severe ammonia levels.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hepatic failure
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001399" target="_blank">
                                Hepatic failure
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001399)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39256843" target="_blank">PMID:39256843</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Five boys presented with early-onset symptoms, including poor appetite, drowsiness, groaning, seizures, and liver failure."</div>
                
                
                <div class="evidence-explanation">Directly reports liver failure as a clinical feature in early-onset OTCD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hyperglutaminemia
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003217" target="_blank">
                                Hyperglutaminemia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003217)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39220945" target="_blank">PMID:39220945</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"all ten early-onset cases had glutamine concentrations above the upper limit"</div>
                
                
                <div class="evidence-explanation">Directly documents hyperglutaminemia in all early-onset OTCD cases.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Oroticaciduria
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003218" target="_blank">
                                Oroticaciduria
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003218)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Oroticaciduria is a well-established diagnostic marker differentiating OTCD from CPS1 deficiency, as accumulated carbamoyl phosphate is diverted into pyrimidine synthesis.</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Low plasma citrulline
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003572" target="_blank">
                                Low plasma citrulline
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003572)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39220945" target="_blank">PMID:39220945</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"only five of them had citrulline concentrations below the lower limit of the reference interval"</div>
                
                
                <div class="evidence-explanation">Documents low citrulline in early-onset OTCD, though not universally present.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">🧬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    OTC variants
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">X-linked inheritance</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31441224" target="_blank">PMID:31441224</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Ornithine transcarbamylase deficiency (OTCD) is a rare X-linked urea cycle disorder."</div>
                
                
                <div class="evidence-explanation">Supports OTC genetic etiology and inheritance architecture.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37146589" target="_blank">PMID:37146589</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"This rare but highly actionable disease can present with severe neonatal onset in males or with later onset in either sex."</div>
                
                
                <div class="evidence-explanation">Supports genotype-phenotype correlation with variable onset and severity.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37146589" target="_blank">PMID:37146589</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-IN_VITRO">In Vitro</span>
                    
                </div>
                
                <div class="evidence-snippet">"our assay distinguishes known benign from pathogenic variants and variants with neonatal onset from late-onset disease presentation"</div>
                
                
                <div class="evidence-explanation">Demonstrates functional assay-based classification of variant severity.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Protein-restricted diet
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000088" target="_blank">
                            MAXO:0000088
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Dietary nitrogen control tailored to age and growth requirements to reduce ammonia production.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37626723" target="_blank">PMID:37626723</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"current dietary and medical treatments may not be sufficient to prevent hyperammonemic episodes"</div>
                
                
                <div class="evidence-explanation">Supports dietary treatment as a standard component of OTCD management, though acknowledging its limitations.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33409766" target="_blank">PMID:33409766</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Treatment consists in adapted nutrition, scavenging agents and dialysis."</div>
                
                
                <div class="evidence-explanation">Confirms adapted nutrition as a core treatment component for UCD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Nitrogen scavenger therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Pharmacologic ammonia-scavenging agents (sodium benzoate, sodium phenylbutyrate, glycerol phenylbutyrate) for chronic and acute management.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33409766" target="_blank">PMID:33409766</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Treatment consists in adapted nutrition, scavenging agents and dialysis."</div>
                
                
                <div class="evidence-explanation">Confirms scavenging agents as a standard treatment modality.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37626723" target="_blank">PMID:37626723</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"current dietary and medical treatments may not be sufficient to prevent hyperammonemic episodes"</div>
                
                
                <div class="evidence-explanation">Supports pharmacologic treatment as standard care while noting its limitations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Arginine supplementation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">L-arginine supplementation to provide substrate for the urea cycle downstream of the OTC block.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33409766" target="_blank">PMID:33409766</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Fifteen patients received l-arginine"</div>
                
                
                <div class="evidence-explanation">Documents L-arginine use in the systematic review of adult UCD case reports.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Acute hyperammonemia management
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Rapid crisis-directed supportive management including protein restriction, glucose infusion, nitrogen scavengers, and emergent hemodialysis when ammonia exceeds 200 micromol/L.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31441224" target="_blank">PMID:31441224</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Maternal OTCD can lead to life-threatening hyperammonemia if untreated."</div>
                
                
                <div class="evidence-explanation">Supports urgent supportive and ammonia-lowering intervention during crises.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33409766" target="_blank">PMID:33409766</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"emergent hemodialysis is mandatory before referral to a reference center if ammonia levels are above 200 µmol/l as the risk of cerebral edema is then above 55%"</div>
                
                
                <div class="evidence-explanation">Provides clinical threshold for emergent hemodialysis in acute hyperammonemia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Liver transplantation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0010039" target="_blank">
                            MAXO:0010039
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Curative metabolic option for selected severe phenotypes; restores full urea cycle capacity and eliminates hyperammonemic risk.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36128655" target="_blank">PMID:36128655</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"For OTCD patients with central nervous system injury, liver transplantation can fundamentally solve the problem of ammonia metabolism in the liver and avoids further damage to the central nervous system caused by hyperammonemia."</div>
                
                
                <div class="evidence-explanation">Directly supports liver transplantation as a disease-modifying option in severe OTCD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37626723" target="_blank">PMID:37626723</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"liver transplantation is the only curative choice but is not widely available due to donor shortage, the need for life-long immunosuppression and technical challenges"</div>
                
                
                <div class="evidence-explanation">Confirms liver transplantation as the only curative treatment while noting practical limitations.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39256843" target="_blank">PMID:39256843</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Three patients survived, and two of them underwent liver transplantation."</div>
                
                
                <div class="evidence-explanation">Documents liver transplantation as a life-saving intervention in OTCD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Genetic counseling
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000079" target="_blank">
                            MAXO:0000079
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Genetic counseling for X-linked inheritance pattern, carrier testing in at-risk females, and prenatal/preconception planning.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31441224" target="_blank">PMID:31441224</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Maternal OTCD is associated with high maternal and neonatal morbidity and mortality when diagnosis is made during pregnancy compared to when diagnosis is known prior to pregnancy."</div>
                
                
                <div class="evidence-explanation">Strongly supports the value of pre-pregnancy diagnosis and genetic counseling for carrier females.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">🔬</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Ammonia
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Increased)</span>
                    
                </div>
                
                <div class="item-desc">Context: Hyperammonemia from impaired urea cycle in OTCD</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37146589" target="_blank">PMID:37146589</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Individuals with neonatal onset appear normal at birth but rapidly develop hyperammonemia, which can progress to cerebral edema, coma, and death"</div>
                
                
                <div class="evidence-explanation">Confirms hyperammonemia as the cardinal biochemical abnormality in OTCD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39256843" target="_blank">PMID:39256843</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"elevated blood ammonia levels serve as a crucial diagnostic clue for OTCD"</div>
                
                
                <div class="evidence-explanation">Directly identifies elevated ammonia as a key diagnostic marker.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Glutamine
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Increased)</span>
                    
                </div>
                
                <div class="item-desc">Context: Elevated plasma glutamine from ammonia detoxification via glutamine synthetase</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39220945" target="_blank">PMID:39220945</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"all ten early-onset cases had glutamine concentrations above the upper limit"</div>
                
                
                <div class="evidence-explanation">Directly documents elevated glutamine in all early-onset OTCD cases.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12136059" target="_blank">PMID:12136059</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The glutamine (Gln) plus glutamate concentration was increased in four patients, which progressed in proportion to the clinical stage."</div>
                
                
                <div class="evidence-explanation">Brain MRS data showing progressive glutamine accumulation correlating with clinical severity.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Citrulline
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Decreased)</span>
                    
                </div>
                
                <div class="item-desc">Context: Low or low-normal plasma citrulline from impaired OTC enzymatic product formation</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39220945" target="_blank">PMID:39220945</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"only five of them had citrulline concentrations below the lower limit of the reference interval"</div>
                
                
                <div class="evidence-explanation">Documents low citrulline in a proportion of early-onset OTCD cases.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39220945" target="_blank">PMID:39220945</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The Cit/Phe ratio was decreased, and the Gln/Cit and Met/Cit ratios were increased in all early-onset OTCD cases"</div>
                
                
                <div class="evidence-explanation">Supports abnormal citrulline ratios as reliable screening markers.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Orotic acid
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Increased)</span>
                    
                </div>
                
                <div class="item-desc">Context: Elevated urinary orotic acid from diversion of carbamoyl phosphate to pyrimidine pathway</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Ornithine Carbamoyltransferase Deficiency
creation_date: &#39;2026-02-23T00:00:00Z&#39;
updated_date: &#39;2026-02-28T02:48:12Z&#39;
category: Mendelian
synonyms:
- OTC deficiency
- Ornithine transcarbamylase deficiency
- OTCD
description: &gt;
  Ornithine carbamoyltransferase deficiency (OTCD) is the most common urea cycle
  disorder, caused by pathogenic variants in the X-linked OTC gene. The encoded
  mitochondrial enzyme catalyzes the conversion of carbamoyl phosphate and
  ornithine to citrulline. Deficiency impairs ureagenesis, producing episodic or
  persistent hyperammonemia with risk of severe neurologic injury. Hemizygous
  males typically present with neonatal-onset disease, whereas heterozygous
  females and males with partial enzyme deficiency may present with later-onset
  intermittent hyperammonemia triggered by catabolic stress.
disease_term:
  preferred_term: ornithine carbamoyltransferase deficiency
  term:
    id: MONDO:0010703
    label: ornithine carbamoyltransferase deficiency
parents:
- Urea Cycle Disorder
- Inborn Error of Metabolism
pathophysiology:
- name: Ornithine carbamoyltransferase molecular function deficiency
  description: &gt;
    Pathogenic OTC variants reduce ornithine carbamoyltransferase enzymatic
    activity in hepatic mitochondria.
  genes:
  - preferred_term: OTC
    term:
      id: hgnc:8512
      label: OTC
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:31441224
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Ornithine transcarbamylase deficiency (OTCD) is a rare X-linked urea cycle disorder.&#34;
    explanation: Supports OTCD as a urea-cycle enzyme deficiency disorder.
  - reference: PMID:31110235
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;carbamoylphosphate synthetase 1 and ornithine transcarbamylase are present in the mitochondrial matrix&#34;
    explanation: Confirms mitochondrial matrix localization of OTC enzyme.
  downstream:
  - target: Impaired citrulline synthesis and reduced urea cycle flux
    description: Reduced OTC activity limits carbamoyl phosphate utilization in ureagenesis.
- name: Impaired citrulline synthesis and reduced urea cycle flux
  description: &gt;
    Reduced OTC activity lowers conversion of ornithine and carbamoyl phosphate
    to citrulline, decreasing urea cycle throughput and predisposing to
    hyperammonemia.
  biological_processes:
  - preferred_term: urea cycle
    term:
      id: GO:0000050
      label: urea cycle
  evidence:
  - reference: PMID:39328593
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;OTCD typically leads to mitochondrial enzyme dysfunction, preventing the synthesis of citrulline from carbamoyl phosphate and ornithine&#34;
    explanation: Directly supports the enzymatic defect blocking citrulline synthesis.
  downstream:
  - target: Hyperammonemic cerebral injury via astrocyte swelling
    description: Reduced ureagenesis increases systemic ammonia burden with CNS toxicity.
  - target: Carbamoyl phosphate diversion to pyrimidine pathway
    description: Unused mitochondrial carbamoyl phosphate is diverted to orotate production.
- name: Hyperammonemic cerebral injury via astrocyte swelling
  description: &gt;
    Recurrent hyperammonemia causes astrocyte swelling and cerebral edema through
    glutamine accumulation. In brain, glutamine synthesis is the only route of
    ammonia detoxification, and excess glutamine acts as an osmolyte causing
    astrocyte swelling and cerebral edema.
  cell_types:
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  biological_processes:
  - preferred_term: glutamine biosynthetic process
    term:
      id: GO:0006541
      label: glutamine biosynthetic process
  evidence:
  - reference: PMID:36128655
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Its clinical manifestations are mainly central nervous system dysfunction caused by high blood ammonia.&#34;
    explanation: Supports ammonia-driven CNS injury as a core downstream mechanism.
  - reference: PMID:34665389
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;severe damage to the central nervous system due to the toxic effects exerted by ammonia on the astrocytes&#34;
    explanation: Directly supports astrocyte-mediated ammonia neurotoxicity.
  - reference: PMID:35733937
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: &#34;in brain glutamine synthesis is the only route of ammonia detoxification, hyperammonemia is as a rule associated with increased brain glutamine content (glutaminosis)&#34;
    explanation: Supports the glutamine trapping hypothesis and osmotic astrocyte swelling mechanism.
  - reference: PMID:33409766
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;emergent hemodialysis is mandatory before referral to a reference center if ammonia levels are above 200 µmol/l as the risk of cerebral edema is then above 55%&#34;
    explanation: Quantifies the high risk of cerebral edema at elevated ammonia levels in adults with UCD.
  downstream:
  - target: Ammonia-induced oxidative stress and mitochondrial dysfunction
- name: Ammonia-induced oxidative stress and mitochondrial dysfunction
  description: &gt;
    Hyperammonemia induces oxidative stress and mitochondrial dysfunction in the
    CNS, contributing to neuronal energy failure and cumulative neurodevelopmental
    impairment.
  biological_processes:
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  evidence:
  - reference: PMID:34665389
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Ammonia is a neurotoxic compound which is detoxified through liver enzymes from urea cycle.&#34;
    explanation: Supports the neurotoxic role of ammonia when hepatic detoxification is impaired.
- name: Carbamoyl phosphate diversion to pyrimidine pathway
  description: &gt;
    When OTC cannot utilize carbamoyl phosphate, excess substrate enters the
    cytosolic pyrimidine biosynthesis pathway, resulting in increased urinary
    orotic acid excretion, a hallmark diagnostic finding in OTCD.
  evidence:
  - reference: PMID:39220945
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;all ten early-onset cases had glutamine concentrations above the upper limit, only five of them had citrulline concentrations below the lower limit&#34;
    explanation: Supports the biochemical pattern of impaired citrulline synthesis with substrate diversion.
phenotypes:
- name: Hyperammonemia
  frequency: VERY_FREQUENT
  description: Marked or intermittent plasma ammonia elevation, the cardinal biochemical feature.
  phenotype_term:
    preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  evidence:
  - reference: PMID:31441224
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Maternal OTCD can lead to life-threatening hyperammonemia if untreated.&#34;
    explanation: Confirms hyperammonemia as a major clinical risk in OTCD.
  - reference: PMID:37146589
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Individuals with neonatal onset appear normal at birth but rapidly develop hyperammonemia, which can progress to cerebral edema, coma, and death&#34;
    explanation: Confirms hyperammonemia as the pivotal early clinical event in neonatal OTCD.
- name: Encephalopathy
  frequency: FREQUENT
  description: Acute encephalopathy during decompensation episodes.
  phenotype_term:
    preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  evidence:
  - reference: PMID:36128655
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Its clinical manifestations are mainly central nervous system dysfunction caused by high blood ammonia.&#34;
    explanation: Supports encephalopathic CNS dysfunction in OTCD.
  - reference: PMID:33409766
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Hyperammonemia caused by a disorder of the urea cycle is a rare cause of metabolic encephalopathy that may be underdiagnosed by the adult intensivists because of its rarity.&#34;
    explanation: Directly identifies UCD-related hyperammonemia as a cause of metabolic encephalopathy.
- name: Vomiting
  frequency: FREQUENT
  description: Emesis associated with metabolic crisis and rising ammonia.
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
  evidence:
  - reference: PMID:36128655
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;His first symptoms were nonprojectile vomiting, followed by irritability and disturbance of consciousness, after which the disease progressed rapidly and finally resulted in a coma.&#34;
    explanation: Directly supports vomiting as an early symptom in hyperammonemic decompensation.
- name: Lethargy
  frequency: FREQUENT
  description: Reduced arousal, progressing to coma in severe episodes.
  phenotype_term:
    preferred_term: Lethargy
    term:
      id: HP:0001254
      label: Lethargy
  evidence:
  - reference: PMID:36128655
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;His first symptoms were nonprojectile vomiting, followed by irritability and disturbance of consciousness, after which the disease progressed rapidly and finally resulted in a coma.&#34;
    explanation: Supports severe neurologic decline during OTCD decompensation episodes.
- name: Seizures
  frequency: FREQUENT
  description: Seizures occurring during hyperammonemic crises.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:39256843
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Five boys presented with early-onset symptoms, including poor appetite, drowsiness, groaning, seizures, and liver failure.&#34;
    explanation: Directly reports seizures as a clinical manifestation in early-onset OTCD.
- name: Coma
  frequency: FREQUENT
  description: Hyperammonemic coma during severe decompensation, particularly in neonatal-onset disease.
  phenotype_term:
    preferred_term: Coma
    term:
      id: HP:0001259
      label: Coma
  evidence:
  - reference: PMID:37146589
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;rapidly develop hyperammonemia, which can progress to cerebral edema, coma, and death&#34;
    explanation: Directly supports coma as a progression of hyperammonemia in OTCD.
  - reference: PMID:36128655
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;the disease progressed rapidly and finally resulted in a coma&#34;
    explanation: Case report documenting progression to coma in late-onset OTCD.
- name: Cerebral edema
  frequency: FREQUENT
  description: &gt;
    Brain swelling secondary to ammonia-driven astrocyte osmotic changes;
    risk exceeds 55% when ammonia levels surpass 200 micromol/L.
  phenotype_term:
    preferred_term: Cerebral edema
    term:
      id: HP:0002181
      label: Cerebral edema
  evidence:
  - reference: PMID:37146589
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;rapidly develop hyperammonemia, which can progress to cerebral edema, coma, and death&#34;
    explanation: Directly names cerebral edema as a complication of hyperammonemia in OTCD.
  - reference: PMID:33409766
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;emergent hemodialysis is mandatory before referral to a reference center if ammonia levels are above 200 µmol/l as the risk of cerebral edema is then above 55%&#34;
    explanation: Quantifies the high risk of cerebral edema at severe ammonia levels.
- name: Global developmental delay
  frequency: OCCASIONAL
  description: Neurodevelopmental delay risk after recurrent or severe crises.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:36128655
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;However, the child is currently mentally retarded, and the language center has not yet fully recovered.&#34;
    explanation: Supports persistent neurodevelopmental impairment after severe OTCD CNS injury.
- name: Hepatic failure
  frequency: OCCASIONAL
  description: Liver failure may occur during severe metabolic decompensation, particularly in early-onset cases.
  phenotype_term:
    preferred_term: Hepatic failure
    term:
      id: HP:0001399
      label: Hepatic failure
  evidence:
  - reference: PMID:39256843
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Five boys presented with early-onset symptoms, including poor appetite, drowsiness, groaning, seizures, and liver failure.&#34;
    explanation: Directly reports liver failure as a clinical feature in early-onset OTCD.
- name: Hyperglutaminemia
  frequency: VERY_FREQUENT
  description: Elevated plasma glutamine from excess ammonia detoxification via glutamine synthetase.
  phenotype_term:
    preferred_term: Hyperglutaminemia
    term:
      id: HP:0003217
      label: Hyperglutaminemia
  evidence:
  - reference: PMID:39220945
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;all ten early-onset cases had glutamine concentrations above the upper limit&#34;
    explanation: Directly documents hyperglutaminemia in all early-onset OTCD cases.
- name: Oroticaciduria
  frequency: VERY_FREQUENT
  description: &gt;
    Increased urinary orotic acid from diversion of accumulated carbamoyl
    phosphate into the pyrimidine biosynthesis pathway; a distinguishing feature
    from CPS1 deficiency.
  phenotype_term:
    preferred_term: Oroticaciduria
    term:
      id: HP:0003218
      label: Oroticaciduria
  notes: Oroticaciduria is a well-established diagnostic marker differentiating OTCD from CPS1 deficiency, as accumulated carbamoyl phosphate is diverted into pyrimidine synthesis.
- name: Low plasma citrulline
  frequency: FREQUENT
  description: Reduced plasma citrulline reflecting impaired OTC enzymatic product formation.
  phenotype_term:
    preferred_term: Low plasma citrulline
    term:
      id: HP:0003572
      label: Low plasma citrulline
  evidence:
  - reference: PMID:39220945
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;only five of them had citrulline concentrations below the lower limit of the reference interval&#34;
    explanation: Documents low citrulline in early-onset OTCD, though not universally present.
- name: Behavioral abnormalities
  frequency: OCCASIONAL
  description: &gt;
    Psychiatric and behavioral disturbances including confusion, agitation,
    and psychotic-like episodes may be the presenting feature of late-onset disease.
  phenotype_term:
    preferred_term: Atypical behavior
    term:
      id: HP:0000708
      label: Atypical behavior
  notes: Behavioral disorders reported in 35% of adult-onset UCD presentations in systematic reviews.
genetic:
- name: OTC variants
  inheritance:
  - name: X-linked inheritance
    evidence:
    - reference: PMID:31441224
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &#34;Ornithine transcarbamylase deficiency (OTCD) is a rare X-linked urea cycle disorder.&#34;
      explanation: Directly supports X-linked inheritance in OTCD.
    - reference: PMID:33409766
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &#34;Urea cycle disorders are autosomal recessive diseases except for ornithine transcarbamylase deficiency (OTCD) that is X-linked.&#34;
      explanation: Confirms OTCD is the only X-linked UCD.
  features: &gt;
    Pathogenic OTC variants produce variable severity from neonatal male
    presentations to later-onset or heterozygous female disease. A high-throughput
    functional assay of 1,570 OTC missense variants distinguished benign from
    pathogenic variants and correlated with neonatal versus late-onset presentations.
  evidence:
  - reference: PMID:31441224
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Ornithine transcarbamylase deficiency (OTCD) is a rare X-linked urea cycle disorder.&#34;
    explanation: Supports OTC genetic etiology and inheritance architecture.
  - reference: PMID:37146589
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;This rare but highly actionable disease can present with severe neonatal onset in males or with later onset in either sex.&#34;
    explanation: Supports genotype-phenotype correlation with variable onset and severity.
  - reference: PMID:37146589
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: &#34;our assay distinguishes known benign from pathogenic variants and variants with neonatal onset from late-onset disease presentation&#34;
    explanation: Demonstrates functional assay-based classification of variant severity.
  - reference: PMID:39256843
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Nine distinct variants of the OTC gene were identified, including two novel mutations&#34;
    explanation: Expands the known OTC mutation spectrum with novel pathogenic variants.
treatments:
- name: Protein-restricted diet
  description: Dietary nitrogen control tailored to age and growth requirements to reduce ammonia production.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  evidence:
  - reference: PMID:37626723
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;current dietary and medical treatments may not be sufficient to prevent hyperammonemic episodes&#34;
    explanation: Supports dietary treatment as a standard component of OTCD management, though acknowledging its limitations.
  - reference: PMID:33409766
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Treatment consists in adapted nutrition, scavenging agents and dialysis.&#34;
    explanation: Confirms adapted nutrition as a core treatment component for UCD.
- name: Nitrogen scavenger therapy
  description: &gt;
    Pharmacologic ammonia-scavenging agents (sodium benzoate, sodium
    phenylbutyrate, glycerol phenylbutyrate) for chronic and acute management.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:33409766
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Treatment consists in adapted nutrition, scavenging agents and dialysis.&#34;
    explanation: Confirms scavenging agents as a standard treatment modality.
  - reference: PMID:37626723
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;current dietary and medical treatments may not be sufficient to prevent hyperammonemic episodes&#34;
    explanation: Supports pharmacologic treatment as standard care while noting its limitations.
- name: Arginine supplementation
  description: &gt;
    L-arginine supplementation to provide substrate for the urea cycle
    downstream of the OTC block.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:33409766
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Fifteen patients received l-arginine&#34;
    explanation: Documents L-arginine use in the systematic review of adult UCD case reports.
- name: Acute hyperammonemia management
  description: &gt;
    Rapid crisis-directed supportive management including protein restriction,
    glucose infusion, nitrogen scavengers, and emergent hemodialysis when ammonia
    exceeds 200 micromol/L.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:31441224
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Maternal OTCD can lead to life-threatening hyperammonemia if untreated.&#34;
    explanation: Supports urgent supportive and ammonia-lowering intervention during crises.
  - reference: PMID:33409766
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;emergent hemodialysis is mandatory before referral to a reference center if ammonia levels are above 200 µmol/l as the risk of cerebral edema is then above 55%&#34;
    explanation: Provides clinical threshold for emergent hemodialysis in acute hyperammonemia.
- name: Liver transplantation
  description: &gt;
    Curative metabolic option for selected severe phenotypes; restores full urea
    cycle capacity and eliminates hyperammonemic risk.
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: MAXO:0010039
      label: organ transplantation
  evidence:
  - reference: PMID:36128655
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;For OTCD patients with central nervous system injury, liver transplantation can fundamentally solve the problem of ammonia metabolism in the liver and avoids further damage to the central nervous system caused by hyperammonemia.&#34;
    explanation: Directly supports liver transplantation as a disease-modifying option in severe OTCD.
  - reference: PMID:37626723
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;liver transplantation is the only curative choice but is not widely available due to donor shortage, the need for life-long immunosuppression and technical challenges&#34;
    explanation: Confirms liver transplantation as the only curative treatment while noting practical limitations.
  - reference: PMID:39256843
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Three patients survived, and two of them underwent liver transplantation.&#34;
    explanation: Documents liver transplantation as a life-saving intervention in OTCD.
- name: Genetic counseling
  description: &gt;
    Genetic counseling for X-linked inheritance pattern, carrier testing in
    at-risk females, and prenatal/preconception planning.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:31441224
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Maternal OTCD is associated with high maternal and neonatal morbidity and mortality when diagnosis is made during pregnancy compared to when diagnosis is known prior to pregnancy.&#34;
    explanation: Strongly supports the value of pre-pregnancy diagnosis and genetic counseling for carrier females.
biochemical:
- name: Ammonia
  presence: Increased
  context: Hyperammonemia from impaired urea cycle in OTCD
  biomarker_term:
    preferred_term: ammonium
    term:
      id: CHEBI:28938
      label: ammonium
  evidence:
  - reference: PMID:37146589
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Individuals with neonatal onset appear normal at birth but rapidly develop hyperammonemia, which can progress to cerebral edema, coma, and death&#34;
    explanation: Confirms hyperammonemia as the cardinal biochemical abnormality in OTCD.
  - reference: PMID:39256843
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;elevated blood ammonia levels serve as a crucial diagnostic clue for OTCD&#34;
    explanation: Directly identifies elevated ammonia as a key diagnostic marker.
- name: Glutamine
  presence: Increased
  context: Elevated plasma glutamine from ammonia detoxification via glutamine synthetase
  biomarker_term:
    preferred_term: glutamine
    term:
      id: CHEBI:28300
      label: glutamine
  evidence:
  - reference: PMID:39220945
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;all ten early-onset cases had glutamine concentrations above the upper limit&#34;
    explanation: Directly documents elevated glutamine in all early-onset OTCD cases.
  - reference: PMID:12136059
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;The glutamine (Gln) plus glutamate concentration was increased in four patients, which progressed in proportion to the clinical stage.&#34;
    explanation: Brain MRS data showing progressive glutamine accumulation correlating with clinical severity.
- name: Citrulline
  presence: Decreased
  context: Low or low-normal plasma citrulline from impaired OTC enzymatic product formation
  biomarker_term:
    preferred_term: citrulline
    term:
      id: CHEBI:18211
      label: citrulline
  evidence:
  - reference: PMID:39220945
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;only five of them had citrulline concentrations below the lower limit of the reference interval&#34;
    explanation: Documents low citrulline in a proportion of early-onset OTCD cases.
  - reference: PMID:39220945
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;The Cit/Phe ratio was decreased, and the Gln/Cit and Met/Cit ratios were increased in all early-onset OTCD cases&#34;
    explanation: Supports abnormal citrulline ratios as reliable screening markers.
- name: Orotic acid
  presence: Increased
  context: Elevated urinary orotic acid from diversion of carbamoyl phosphate to pyrimidine pathway
  biomarker_term:
    preferred_term: orotic acid
    term:
      id: CHEBI:16742
      label: orotic acid
  notes: Elevated urinary orotic acid in OTCD results from accumulated carbamoyl phosphate being diverted into pyrimidine biosynthesis; this is a textbook diagnostic finding distinguishing OTCD from CPS1 deficiency.
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Ornithine_Carbamoyltransferase_Deficiency.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>